A 52-year-old man with metastatic pancreatic adenocarcinoma (stage IV, liver and peritoneal involvement) presents with acute onset of dyspnea, chest pain, and hemoptysis. He also reports oozing from a recent tooth extraction site and dark urine. Vital signs: BP 88/54 mmHg, HR 126/min, RR 28/min, O₂ saturation 88% on room air. Laboratory: Hb 8.9 g/dL, WBC 14,200/μL, platelets 32,000/μL, PT 22 sec (control 12), aPTT 68 sec (control 36), fibrinogen 78 mg/dL, D-dimer 8.5 μg/mL (normal <0.5). Chest X-ray shows bilateral infiltrates. What is the most likely diagnosis?

Explanation

## Clinical Diagnosis: DIC with ARDS in Malignancy ### Pathophysiologic Context **Key Point:** Solid tumors, particularly pancreatic and lung cancers, are potent triggers of DIC through release of tissue factor (TF) and cancer procoagulant from tumor cells and tumor-associated macrophages. Pancreatic adenocarcinoma has one of the highest DIC incidences among solid malignancies (up to 50–70% in advanced disease). Metastatic burden amplifies procoagulant activity, leading to systemic activation of coagulation and consumption of platelets, fibrinogen, and clotting factors. ### ISTH DIC Scoring: Overt DIC Confirmed | Component | Value | Points | |-----------|-------|--------| | Platelet count | 32,000/μL | +1 | | D-dimer/FDP elevation | 8.5 μg/mL (markedly elevated) | +3 | | PT prolongation | 22 sec (+10 sec above control) | +1 | | Fibrinogen | 78 mg/dL (<100 mg/dL) | +1 | | **Total Score** | — | **≥6 (overt DIC)** | ### Multi-Organ Involvement: DIC Manifestations 1. **Pulmonary:** Bilateral infiltrates + hemoptysis + hypoxemia → **DIC-induced ARDS** - Microthrombi in pulmonary capillaries → capillary leak, pulmonary edema - Platelet and fibrin deposition → acute lung injury 2. **Hematologic:** Thrombocytopenia (32,000) + anemia (Hb 8.9) → consumption coagulopathy 3. **Bleeding:** Gum oozing, dark urine (hematuria) → factor depletion + microthrombi 4. **Hemodynamic:** Hypotension (88/54), tachycardia (126), tachypnea (28) → sepsis-like state, tissue hypoperfusion **High-Yield:** The triad of **advanced malignancy + coagulopathy + bilateral pulmonary infiltrates** is classic for DIC-ARDS. ### Pathophysiology of DIC-ARDS ```mermaid flowchart TD A[Pancreatic adenocarcinoma]:::outcome --> B[Release of tissue factor & cancer procoagulant]:::outcome B --> C[Systemic coagulation activation]:::action C --> D[Platelet & fibrinogen consumption]:::outcome C --> E[Fibrin microthrombi formation]:::outcome E --> F[Pulmonary capillary occlusion]:::outcome F --> G[Capillary leak & endothelial injury]:::outcome G --> H[ARDS]:::urgent D --> I[Thrombocytopenia & hypofibrinogenemia]:::outcome I --> J[Bleeding manifestations]:::urgent C --> K[Factor consumption]:::outcome K --> L[Prolonged PT/aPTT]:::outcome ``` ### Management Strategy 1. **Supportive care (first-line):** - Platelet transfusion (target >20,000/μL for bleeding; >50,000/μL for ARDS) - FFP + cryoprecipitate for fibrinogen replacement - Mechanical ventilation for ARDS (lung-protective strategy) 2. **Anticoagulation (controversial but considered):** - Low-dose unfractionated heparin (5–10 units/kg/hr) to block ongoing thrombin generation - Rationale: Prevent further microthrombi formation while supporting bleeding with transfusions 3. **Treat underlying malignancy:** - Palliative chemotherapy or clinical trial enrollment - DIC often signals end-stage disease; prognosis poor **Clinical Pearl:** DIC in solid tumors carries a mortality rate of 40–60% despite aggressive supportive care. The presence of ARDS worsens prognosis further. Definitive treatment of the cancer (if feasible) is the only way to halt DIC progression.